BioCentury
ARTICLE | Deals

AstraZeneca eyes August trial start for COVID-19 mAb pair

June 9, 2020 10:45 PM UTC

AstraZeneca is joining the COVID-19 neutralizing antibody race with a pair of candidates licensed from Vanderbilt to treat or prevent the infection that are slated to begin clinical testing in August.

The company also announced an interagency agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Advanced Research Projects Agency (DARPA) to support development of a mAb against SARS-CoV-2. That includes supporting manufacturing for the Phase I trial...